Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable patent settlement and future growth.
Maze Therapeutics IPOs at $487M, targeting APOL1 Kidney Disease with MZE829 in Phase 2. Click here to read an analysis of MAZE stock now.
Hosted on MSN3mon
Maze Therapeutics raises $115m to advance kidney disease candidatesaimed at treating Pompe disease. "Maze Therapeutics raises $115m to advance kidney disease candidates" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
AKD, a subset of chronic kidney disease affects over one million ... This trial is part of the company's efforts as an oral treatment for Pompe disease. "Maze Therapeutics doses first subject ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback